The content on this site is intended for healthcare professionals only
Dr Cathy Eng discusses a study into trifluridine/tipiracil plus bevacizumab (FTD/TPI + BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer.
The primary outcome was that the meta-analysis study suggested that FTD/TPI + BEV provides benefits over FTD/TPI in patients with refractory mCRC and has a similar safety profile, but it is associated with a higher rate of grade ≥3 neutropenia.
Dr Eng concludes the by discussing the significance of the study findings
Watch Dr Yoshino's press conference here
Watch Dr Yoshino's interview on the study here
Watch Dr Cremolini comment on the study here
Read the news story on the study here
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Olaparib plus ceralasertib might benefit paediatric cancer patients with DNA repair-deficient tumours
Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG
